Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-06-30
2011-12-20
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S805000, C424S810000, C514S001700
Reexamination Certificate
active
08080249
ABSTRACT:
The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status/with a therapeutically effective amount of an anti-IgE Ênoiety. In accordance with the invention, COFD patients with sn elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found, to be useful ioÊ the treatment of COPD patients regardless of their skin test results arid/or in vitro reactivity to a perennial aeroallergen. Anti-ÊgE moieties, in accordance With the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal iirunuitoglobulln E (e.g., human imntnnoglQbulin E) such as humanized arrti-IgEy humanized murine monoclonal antibody, and/or Qmalizumab.
REFERENCES:
patent: 5994511 (1999-11-01), Lowman et al.
patent: 2005/0026881 (2005-02-01), Robinson et al.
patent: 2005/0158303 (2005-07-01), Liu et al.
patent: 2005/0261208 (2005-11-01), Robinson et al.
patent: WO 9304173 (1993-03-01), None
patent: WO 9967293 (1999-12-01), None
Risk et al. Chest, vol. 126, No. 4, Oct. 2004 supplement, p. 839s.
Risk et al. Chest, vol. 128, No. 4, Oct. 2005 supplement, p. 243s.
Itabashi et al., Respiration. 1990;57(6):384-8.
International Search Report for related PCT Application No. PCT/US2006/25654, dated May 15, 2008, (3 pages).
Written Opinion of the International Searching Authority for related PCT Application No. PCT/US2006/25654, dated May 15, 2008, (5 pages).
Celedon et al., Eur. Respir. J. 14, pp. 1009-1014 (1999).
Groneberg, D. et al., Respiratory Research, 5(1):18, pp. 1-16 (Nov. 2, 2004).
Lewis et al., Chest, 119(1), pp. 105-114 (2001).
Bleecker Eugene, “Similarities and Differences in Asthma and COPD. The Dutch Hypothesis,” Chest 2004:126:93S-95S.
Postma et at “Rationale for the Dutch Hypothesis,” Chest 2004; 126: 965-104S.
Burrows et al., “Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to Allergens,” The New Enge J Med 1989; 320: 271-277.
Lapparre et al., “Dissociation of Lung Function and Airway Inflammation in Chronic Obstructive Disease,” Am J Respir Crit Care Med 2004; 170: 499-504.
Rohde et al., “Increased IgE-antibodies toStaphylococcus aureusenterotoxins in patients with COPD,” Respiratory Medicine 2004; 98: 858-64.
Greenberger PA, “Allergic bronchopulmonary aspergillosis,” J Allergy Clin Immunol 2002: 110: 685-92.
Dakhama et al., “The Role of Virus-Specific Immunoglobulin E in Airway Hyperresponsiveness,” Am J Respir Crit Care Med 2004; 171: 952-959.
Milgrom et al. “Treatments of allergic asthma with Monoclonal anti IgE antibody,” The N Engl J Med 1999: 341: 1966-1973.
Soler et al., “The Anti-IgE Antibody Omalizumab Reduces Exacerbations and Steroid Requirement in Allergic Asthmatics,” Eur Resp J 2001; 18: 254-261.
Busse et al., “Omalizumab, Anti-E Recombinant Humanized Monoclonal Antibody for the Treatment of Severe Allergic Asthma,” J Allergy Clin Immunal 2001; 184-190.
Holgate et al., “Efficacy of Omalizumab Anti-Immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Severe Asthma-related Morbidity and Mortality,” Current Medical Research and Opinions 2001; 17(4): 233-240.
Bousquet et al., “Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients with Allergic Asthma,” Chest 2004; 125: 1378-1386.
Djukanovic et al. “Effects of Treatment with Anti-Immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma,” Am J Respir Crit Care Med 2004; 170: 583-593.
Hargreave et al., “Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease,” Am J Respir Crit Care Med 1999; 160: S53-S57.
Fabbri et al. “Similarities and differences between exacerbations of asthma and chronic obstructive pulmonary disease,” Thorax 1998; 53-803-808.
Elias J. “The Relationship between Asthma and COPD. Lessons from Transgenic Mice,” Chest 2004; 126: 111S-116S.
Barnes PJ. “Chronic Obstructive Pulmonary Disease,” The N Engl J Med 2000; 343: 269-280.
Sciurba F. “Physiologic Similarities and Differences Between Asthma and COPD,” Chest 2004; 126: 117S-124S.
Mitsunobu et al., “Influence of long-term cigarette smoking on immunoglobulin E-mediated allergy, pulmonary function, and high resolution computed tomography lung densitometry in elderly patients with asthma,” Clin Exp Allergy 2004; 34: 59-64.
McDermott Will & Emery LLP
Szperka Michael
LandOfFree
Methods to treating chronic obstructive pulmonary disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to treating chronic obstructive pulmonary disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to treating chronic obstructive pulmonary disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4269262